Spinal Cord Injury - Pipeline Review, H1 2015
Summary
Global Markets Directs, Spinal Cord Injury - Pipeline Review, H1 2015, provides an overview of the Spinal Cord Injurys therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Cord Injury and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Spinal Cord Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Spinal Cord Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Spinal Cord Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Spinal Cord Injury
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Spinal Cord Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 8
Global Markets Direct Report Coverage 8
Spinal Cord Injury Overview 9
Therapeutics Development 10
Pipeline Products for Spinal Cord Injury - Overview 10
Pipeline Products for Spinal Cord Injury - Comparative Analysis 11
Spinal Cord Injury - Therapeutics under Development by Companies 12
Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes 17
Spinal Cord Injury - Pipeline Products Glance 19
Clinical Stage Products 19
Early Stage Products 20
Spinal Cord Injury - Products under Development by Companies 21
Spinal Cord Injury - Products under Investigation by Universities/Institutes 25
Spinal Cord Injury - Companies Involved in Therapeutics Development 27
Acorda Therapeutics, Inc. 27
Asubio Pharma Co., Ltd. 28
Athersys, Inc. 29
Axerion Therapeutics, Inc. 30
BioArctic Neuroscience AB 31
Faron Pharmaceuticals Oy 32
FirstString Research, Inc. 33
Genervon Biopharmaceuticals, LLC 34
Grupo Ferrer Internacional, S.A. 35
Hemostemix Ltd 36
Histocell S.L. 37
Intellipharmaceutics International Inc. 38
K-Stemcell Co., Ltd. 39
Kadimastem Ltd. 40
Kringle Pharma, Inc. 41
Lipopharma Therapeutics SL 42
Lpath, Inc. 43
MandalMed, Inc. 44
Mapreg S.A.S. 45
Mitsubishi Tanabe Pharma Corporation 46
Neuralstem, Inc. 47
Neuronax SAS 48
Omeros Corporation 49
PharmatrophiX, Inc. 50
Pharmicell Co., Ltd. 51
Q Therapeutics, Inc. 52
Quark Pharmaceuticals, Inc. 53
Remedy Pharmaceuticals, Inc. 54
RhinoCyte, Inc. 55
SanBio, Inc. 56
Sirnaomics, Inc. 57
StemCells, Inc. 58
Stemedica Cell Technologies, Inc. 59
TissueGene, Inc. 60
Vertex Pharmaceuticals Incorporated 61
Vicore Pharma AB 62
Spinal Cord Injury - Therapeutics Assessment 63
Assessment by Monotherapy Products 63
Assessment by Combination Products 64
Assessment by Target 65
Assessment by Mechanism of Action 67
Assessment by Route of Administration 69
Assessment by Molecule Type 71
Drug Profiles 73
(buspirone + levodopa + carbidopa) - Drug Profile 73
ACTX-08 - Drug Profile 75
Antibody to Inhibit RGM for Spinal Cord Injury - Drug Profile 76
AP-325 - Drug Profile 77
AST-OPC-1 - Drug Profile 78
Astrostem - Drug Profile 80
AX-007 - Drug Profile 81
BA-277 - Drug Profile 82
BA-434 - Drug Profile 83
C-21 - Drug Profile 84
Cell Therapy for Spinal Cord Injury - Drug Profile 86
Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 87
Cerecellgram-Spine - Drug Profile 88
CHEC-7 - Drug Profile 89
CHEC-9 - Drug Profile 90
chondroitinase ABC nanosphere - Drug Profile 92
cimaglermin alfa - Drug Profile 93
CLR-01 - Drug Profile 95
CM-101 - Drug Profile 97
Drug for Spinal Cord Injury - Drug Profile 99
Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile 100
FIB-117 - Drug Profile 101
glyburide - Drug Profile 102
GM-603 - Drug Profile 104
HBN-1 - Drug Profile 105
HC-016 - Drug Profile 106
HuCNS-SC - Drug Profile 107
ICCN-100 - Drug Profile 109
IMS-001 - Drug Profile 110
IMS-002 - Drug Profile 111
interferon beta-1a - Drug Profile 112
KP-100IT - Drug Profile 114
LM11A-31 - Drug Profile 116
LPA-181 - Drug Profile 117
Lpathomab - Drug Profile 118
MAP-4343 - Drug Profile 119
MultiStem - Drug Profile 120
NCP-01 - Drug Profile 123
Neural Stem Cells - Drug Profile 124
neurovitas - Drug Profile 126
NgR(310)ecto-Fc - Drug Profile 127
NRP-2945 - Drug Profile 129
NSI-566 - Drug Profile 131
NX-210 - Drug Profile 133
Oligonucleotide for Central Nervous System and Metabolic Disorders - Drug Profile 134
Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury - Drug Profile 135
Peptides for Central Nervous System and Musculoskeletal Disorders - Drug Profile 136
pregabalin ER - Drug Profile 137
PT-00114 - Drug Profile 138
Q-Cells - Drug Profile 139
Recombinant Protein for Spinal Cord Injury - Drug Profile 141
SB-618 - Drug Profile 142
SB-623 - Drug Profile 143
SC-0806 - Drug Profile 145
siRNA for CNS Disorders - Drug Profile 147
Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 148
Small Molecules for Spinal Cord Injury - Drug Profile 149
Stem Cell Therapy for Acute Spinal Cord Injury - Drug Profile 150
Stem Cell Therapy for CNS Disorders - Drug Profile 151
Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile 152
Stem Cell Therapy for Spinal Cord Injury - Drug Profile 154
Stem Cell Therapy for Spinal Cord Injury - Drug Profile 155
Stem Cell Therapy Program for Neurodegenerative Diseases - Drug Profile 156
STP-805 - Drug Profile 157
SUN-13837 - Drug Profile 158
Synthetic Peptide for Spinal Cord Injuries - Drug Profile 159
Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile 160
Tenascin-C Fragments for Spinal Cord Injury - Drug Profile 161
TG-N - Drug Profile 163
UH-0113 - Drug Profile 164
UH-0213 - Drug Profile 165
VX-210 - Drug Profile 166
Spinal Cord Injury - Recent Pipeline Updates 169
Spinal Cord Injury - Dormant Projects 204
Spinal Cord Injury - Discontinued Products 208
Spinal Cord Injury - Product Development Milestones 209
Featured News & Press Releases 209
Appendix 219
Methodology 219
Coverage 219
Secondary Research 219
Primary Research 219
Expert Panel Validation 219
Contact Us 219
Disclaimer 220
List Of Tables
Number of Products under Development for Spinal Cord Injury, H1 2015 15
Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H1 2015 16
Number of Products under Development by Companies, H1 2015 18
Number of Products under Development by Companies, H1 2015 (Contd..1) 19
Number of Products under Development by Companies, H1 2015 (Contd..2) 20
Number of Products under Development by Companies, H1 2015 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2015 23
Comparative Analysis by Clinical Stage Development, H1 2015 24
Comparative Analysis by Early Stage Development, H1 2015 25
Products under Development by Companies, H1 2015 26
Products under Development by Companies, H1 2015 (Contd..1) 27
Products under Development by Companies, H1 2015 (Contd..2) 28
Products under Development by Companies, H1 2015 (Contd..3) 29
Products under Investigation by Universities/Institutes, H1 2015 30
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 31
Spinal Cord Injury - Pipeline by Acorda Therapeutics, Inc., H1 2015 32
Spinal Cord Injury - Pipeline by Asubio Pharma Co., Ltd., H1 2015 33
Spinal Cord Injury - Pipeline by Athersys, Inc., H1 2015 34
Spinal Cord Injury - Pipeline by Axerion Therapeutics, Inc., H1 2015 35
Spinal Cord Injury - Pipeline by BioArctic Neuroscience AB, H1 2015 36
Spinal Cord Injury - Pipeline by Faron Pharmaceuticals Oy, H1 2015 37
Spinal Cord Injury - Pipeline by FirstString Research, Inc., H1 2015 38
Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2015 39
Spinal Cord Injury - Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 40
Spinal Cord Injury - Pipeline by Hemostemix Ltd, H1 2015 41
Spinal Cord Injury - Pipeline by Histocell S.L., H1 2015 42
Spinal Cord Injury - Pipeline by Intellipharmaceutics International Inc., H1 2015 43
Spinal Cord Injury - Pipeline by K-Stemcell Co., Ltd., H1 2015 44
Spinal Cord Injury - Pipeline by Kadimastem Ltd., H1 2015 45
Spinal Cord Injury - Pipeline by Kringle Pharma, Inc., H1 2015 46
Spinal Cord Injury - Pipeline by Lipopharma Therapeutics SL, H1 2015 47
Spinal Cord Injury - Pipeline by Lpath, Inc., H1 2015 48
Spinal Cord Injury - Pipeline by MandalMed, Inc., H1 2015 49
Spinal Cord Injury - Pipeline by Mapreg S.A.S., H1 2015 50
Spinal Cord Injury - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 51
Spinal Cord Injury - Pipeline by Neuralstem, Inc., H1 2015 52
Spinal Cord Injury - Pipeline by Neuronax SAS, H1 2015 53
Spinal Cord Injury - Pipeline by Omeros Corporation, H1 2015 54
Spinal Cord Injury - Pipeline by PharmatrophiX, Inc., H1 2015 55
Spinal Cord Injury - Pipeline by Pharmicell Co., Ltd., H1 2015 56
Spinal Cord Injury - Pipeline by Q Therapeutics, Inc., H1 2015 57
Spinal Cord Injury - Pipeline by Quark Pharmaceuticals, Inc., H1 2015 58
Spinal Cord Injury - Pipeline by Remedy Pharmaceuticals, Inc., H1 2015 59
Spinal Cord Injury - Pipeline by RhinoCyte, Inc., H1 2015 60
Spinal Cord Injury - Pipeline by SanBio, Inc., H1 2015 61
Spinal Cord Injury - Pipeline by Sirnaomics, Inc., H1 2015 62
Spinal Cord Injury - Pipeline by StemCells, Inc., H1 2015 63
Spinal Cord Injury - Pipeline by Stemedica Cell Technologies, Inc., H1 2015 64
Spinal Cord Injury - Pipeline by TissueGene, Inc., H1 2015 65
Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 66
Spinal Cord Injury - Pipeline by Vicore Pharma AB, H1 2015 67
Assessment by Monotherapy Products, H1 2015 68
Assessment by Combination Products, H1 2015 69
Number of Products by Stage and Target, H1 2015 71
Number of Products by Stage and Mechanism of Action, H1 2015 73
Number of Products by Stage and Route of Administration, H1 2015 75
Number of Products by Stage and Molecule Type, H1 2015 77
Spinal Cord Injury Therapeutics - Recent Pipeline Updates, H1 2015 174
Spinal Cord Injury - Dormant Projects, H1 2015 209
Spinal Cord Injury - Dormant Projects (Contd..1), H1 2015 210
Spinal Cord Injury - Dormant Projects (Contd..2), H1 2015 211
Spinal Cord Injury - Dormant Projects (Contd..3), H1 2015 212
Spinal Cord Injury - Discontinued Products, H1 2015 213
List Of Figures
List of Figures
Number of Products under Development for Spinal Cord Injury, H1 2015 15
Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H1 2015 16
Number of Products under Development by Companies, H1 2015 17
Number of Products under Investigation by Universities/Institutes, H1 2015 22
Comparative Analysis by Clinical Stage Development, H1 2015 24
Comparative Analysis by Early Stage Products, H1 2015 25
Assessment by Monotherapy Products, H1 2015 68
Number of Products by Top 10 Targets, H1 2015 70
Number of Products by Stage and Top 10 Targets, H1 2015 70
Number of Products by Top 10 Mechanism of Actions, H1 2015 72
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 72
Number of Products by Top 10 Routes of Administration, H1 2015 74
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 74
Number of Products by Top 10 Molecule Types, H1 2015 76
Number of Products by Stage and Top 10 Molecule Types, H1 2015 76
